The estimated Net Worth of Arthur M Pappas is at least $4.08 Milion dollars as of 23 October 2013. Arthur Pappas owns over 216,840 units of Chimerix Inc stock worth over $714,398 and over the last 12 years Arthur sold CMRX stock worth over $3,363,188.
Arthur has made over 1 trades of the Chimerix Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Arthur sold 216,840 units of CMRX stock worth $3,363,188 on 23 October 2013.
The largest trade Arthur's ever made was selling 216,840 units of Chimerix Inc stock on 23 October 2013 worth over $3,363,188. On average, Arthur trades about 108,420 units every 0 days since 2013. As of 23 October 2013 Arthur still owns at least 830,695 units of Chimerix Inc stock.
You can see the complete history of Arthur Pappas stock trades at the bottom of the page.
Arthur's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 340, DURHAM,, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex a Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: